Clinical-stage biopharmaceutical company ReAlta Life Sciences Inc announced on Thursday that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (pegtarazimod) for the treatment of graft-versus-host disease (GvHD).
This designation follows preliminary data from the company's ongoing Phase 2 trial in steroid-refractory acute GvHD patients.
ReAlta is enrolling patients in an open-label Phase 2 trial across the United States, Germany, and Spain, with additional data expected in 2026. In August 2024, the US Food and Drug Administration also granted Orphan Drug Designation and Fast Track Designation for pegtarazimod in acute GvHD.
The EMA's orphan status is reserved for therapies targeting rare, life-threatening, or chronically debilitating diseases affecting fewer than five in 10,000 people in the EU. Benefits include reduced regulatory fees, protocol assistance, and up to 10 years of market exclusivity upon approval.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval